Arcturus Therapeutics (NASDAQ:ARCT) shares surged 9.8% on Tuesday on dosing in two mid-stage clinical studies.
Arcturus on Monday announced the initiation of dosing in Phase 2 multiple ascending dose studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) deficiency.
This development has placed Arcturus on a trajectory to publish interim results within the first half of this year.
The biotechnology firm’s stock, which experienced a nearly 50% decline over the course of 2024, is currently on track for its fifth consecutive day of gains.
“ARCT-032 has the potential to address the significant unmet medical need in the CF community for those who do not qualify for or benefit from available treatment options,” Pad Chivukula, Chief Scientific Officer of Arcturus said in a press release.
As the market awaits the interim results of the clinical studies, Arcturus Therapeutics’s current upward trend in stock price underscores the critical nature of clinical milestones in determining the valuation of biotech companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
